MiniMed Group Inc (MMED) Stock AnalysisMMEDStock AnalysisMiniMed Group Inc

MiniMed Group, Inc. is a medical technology company, which develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear. It operates in the Healthcare sector.

MiniMed Group, Inc. (MMED) is a good buy right now, trading at $20.1 with an RSI of 58.8 indicating a healthy momentum. The forward P/E ratio is 0, reflecting potential for growth as the company restructures and expands its product offerings. Despite recent losses, the gross margin has been stable at around 57% in Q2 2026, and analysts project a price target of $25, which implies a 24% upside from the current price. The main risk is the negative net income of -185 million USD in Q4 2026, which highlights ongoing financial challenges that investors should monitor closely.